Evidence map›Paper›PMID 29847177›Full record

ArticleDrug delivery2018

l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells.

Shiwei Niu, David H Bremner, Junzi Wu, Jianrong Wu, Haijun Wang, Heyu Li, Qianqian Qian, Hong Zheng, Limin Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shiwei Niua College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai , PR China.
David H Bremnerb School of Science, Engineering and Technology , Abertay University , Dundee , Scotland, UK.
Junzi Wua College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai , PR China.
Jianrong Wua College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai , PR China.
Haijun Wanga College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai , PR China.
Heyu Lia College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai , PR China.
Qianqian Qiana College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai , PR China.
Hong Zhengc Department of Experimental Animal Science , Kunming Medical University , Kunming , PR China.
Limin Zhua College of Chemistry, Chemical Engineering and Biotechnology , Donghua University , Shanghai , PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticles and macromolecular carriers have been widely used to increase the efficacy of chemotherapeutics, largely through passive accumulation provided by their enhanced permeability and retention effect. However, the therapeutic efficacy of nanoscale anticancer drug delivery systems is severely truncated by their low tumor-targetability and inefficient drug release at the target site. Here, the design and development of novel l-peptide functionalized dual-responsive nanoparticles (l-CS-g-PNIPAM-PTX) for active targeting and effective treatment of GRP78-overexpressing human breast cancer in vitro and in vivo are reported. l-CS-g-PNIPAM-PTX NPs have a relative high drug loading (13.5%) and excellent encapsulation efficiency (74.3%) and an average diameter of 275 nm. The release of PTX is slow at pH 7.4 and 25 °C but greatly accelerated at pH 5.0 and 37 °C. MTT assays and confocal experiments showed that the l-CS-g-PNIPAM-PTX NPs possessed high targetability and antitumor activity toward GRP78 overexpressing MDA-MB-231 human breast cancer cells. As expected, l-CS-g-PNIPAM-PTX NPs could effectively treat mice bearing MDA-MB-231 human breast tumor xenografts with little side effects, resulting in complete inhibition of tumor growth and a high survival rate over an experimental period of 60 days. These results indicate that l-peptide-functionalized acid - and thermally activated - PTX prodrug NPs have a great potential for targeted chemotherapy in breast cancer.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBreast NeoplasmsCell Line, TumorCell SurvivalDelayed-Action PreparationsDrug Delivery SystemsDrug LiberationEndoplasmic Reticulum Chaperone BiPFemaleHumansMiceMice, NudeMyelin Basic ProteinNanoparticlesAntineoplastic AgentsDelayed-Action PreparationsEndoplasmic Reticulum Chaperone BiPHSPA5 protein, humanHspa5 protein, mouseMyelin Basic ProteinPaclitaxelPeptide Fragmentspeptide LProdrugsanticancer efficacyapoptosisdual-responsivel-Peptidenanoparticles

Identifiers

PMID29847177
PMCPMC6060704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.